The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift.
•The duration of this study is 3 months. This includes:
* Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle.
* Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments.
* Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.

开始日期2026-05-25

申办/合作机构

University of Pittsburgh

[+1]

NCT07537088

/ Not yet recruiting临床4期IIT

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

The purpose of this study is to evaluate whether adding dulaglutide to the combination therapy of Sodium-Glucose Co-Transporter 2 Inhibitors(SGLT2i) and finerenone can provide additional kidney protection and safety for Chinese adults with Type 2 Diabetes Mellitus(T2DM) and Chronic Kidney Disease(CKD). Eligible participants will be adults with T2DM and mild-to-moderate CKD who have been receiving SGLT2 inhibitor plus finerenone for at least 3 months on the basis of maximum tolerated dose of renin-angiotensin system inhibitor (RASi). Participants will be randomly assigned to either continue the original regimen or to receive add-on therapy with dulaglutide.The study will last for 26 weeks, with participants required to attend scheduled visits for efficacy and safety assessments at Week 13 (±1 week) and Week 26 (±1 week, final visit).

开始日期2026-05-01

申办/合作机构

皖南医学院

NL-OMON58608

/ SuspendedN/A

Uncovering the impact of incretins on fat-free mass, muscle strength and functionalcapacity - Impact of GLP-1 RAs on body composition and physical function

开始日期2026-05-01

申办/合作机构

Radboud Universitair Medisch Centrum

100 项与度拉糖肽相关的临床结果

登录后查看更多信息

100 项与度拉糖肽相关的转化医学

登录后查看更多信息

100 项与度拉糖肽相关的专利（医药）

登录后查看更多信息

1,614

项与度拉糖肽相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Calculating cost per event avoided using a composite number needed to treat

Article

作者: Wang, Julia ; Bhavsar, Jigish ; Toliver, Joshua ; Sullivan, Sean D.

OBJECTIVE:

Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials. This approach, although widely used, does not reflect the complete value of a treatment, as it does not consider outcomes beyond the primary endpoints. This research aims to overcome this limitation by developing multiple composite NNTs to derive the CPEA to estimate a total value of semaglutide and dulaglutide in people with established cardiovascular disease.

METHODS:

Two cardiovascular outcomes trials were selected, SELECT (NCT03574597, semaglutide 2.4 mg) and REWIND (NCT01394952, dulaglutide 1.5 mg). NNT was calculated as NNT = 1/ARR where ARR = control event rate - experimental event rate. NNT was estimated for 3-point major adverse cardiovascular events (MACE-3; primary endpoint of the trials), 5-point MACE (MACE-5), and cardiovascular-kidney-metabolic events (CKM). CPEA of MACE-3, MACE-5, and CKM was calculated as NNT*duration of mean follow-up (semaglutide) or duration of median follow-up (dulaglutide)*estimated net price.

RESULTS:

The NNT decreased as the number of outcomes in the composite endpoint increased, where NNT_MACE-3, NNT_MACE-5, and NNT_CKM were 67, 49, and 8 for semaglutide, and 72, 64, and 23 for dulaglutide, respectively. Similarly, the CPEA decreased as the number of outcomes in the composite endpoint increased, where the CPEA for MACE-3, MACE-5 and CKM calculations were $1,662,001, $1,232,417, and $190,387 for semaglutide and $1,884,013, $1,670,366, and $607,886 for dulaglutide.

CONCLUSIONS:

This research illustrates the limitations of using a NNT focused only on the primary endpoint, as it does not capture the total benefit of the treatment. When considering the value of treatments through NNT or CPEA analyses, a composite endpoint capturing broader benefit should be utilized.

2026-12-31·ANNALS OF MEDICINE

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers

Review

作者: Chikatimalla, Rahul ; Aggarwal, Kanishk ; Shah, Twinkle ; Perry, Griffin ; Shah, Ashka ; Banker, Himanshi ; Jain, Rohit

OBJECTIVES:

To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention.

METHODS:

A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy.

RESULTS:

GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities.

CONCLUSION:

GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.

2026-09-01·JOURNAL OF GASTROINTESTINAL SURGERY

Cancer risk of glucagon-like peptide-1 receptor agonists for obesity: comparison with bariatric surgery and other weight-loss drugs

Article

作者: Sears, Olivia ; Bitar, Elio R ; El Moheb, Mohamad ; McKee, Kellyn ; Besir, Karim ; van der Windt, Dirk J ; Tsung, Allan ; Ruff, Samantha M ; Cummins, Kaelyn C

BACKGROUND:

Obesity is associated with an increased risk of several cancers, including colorectal cancer (CRC), pancreatic cancer, and hepatocellular carcinoma (HCC). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been linked to a lower risk of certain obesity-associated cancers, but most studies have focused on patients with diabetes. Their impact on nondiabetic patients using GLP-1 RAs for weight loss remains unclear.

METHODS:

Using the TriNetX Research network, we conducted a retrospective cohort study of nondiabetic adults with obesity who received semaglutide or tirzepatide, underwent bariatric surgery, or used other weight-loss medications (orlistat, phentermine/topiramate, or naltrexone/bupropion). Patients were stratified by GLP-1 RA dose (any vs therapeutic) and propensity-score matched. Cancer incidence was assessed using Kaplan-Meier analysis and Cox proportional hazards models.

RESULTS:

We identified 662,013 GLP-1 RA users, 272,343 bariatric surgery patients, and 158,446 users of other weight-loss medications. Compared with bariatric surgery, therapeutic-dose GLP-1 RA use was associated with a lower incidence of CRC (hazard ratio [HR], 0.72; P =.038) and pancreatic cancer (HR, 0.63; P =.041), but not HCC. Compared with other weight-loss medications, therapeutic-dose GLP-1 RAs were associated with a lower CRC risk (HR, 0.68; P =.008), without significant differences in pancreatic or liver cancer. The use of any dose was not associated with significant differences.

CONCLUSION:

Therapeutic-dose GLP-1 RA use was associated with a lower incidence of CRC and pancreatic cancer compared with bariatric surgery and with a lower incidence of CRC compared with other weight-loss medications. These findings suggest that GLP-1 RA use is not associated with an increased cancer risk and raise the possibility that therapeutic-dose treatment may be associated with a lower cancer incidence.

2,170

项与度拉糖肽相关的新闻（医药）

2026-09-07

·国际糖尿病idiabetes

降糖、减重、护肝、护心——有没有办法同时兼顾？新共识给出“多靶点”答案

点击“蓝字”关注我们编者按： 2型糖尿病、肥胖症、代谢功能障碍相关脂肪性肝病（MASLD）、慢性肾脏病和心力衰竭常共存，仅观察糖化血红蛋白（HbA1c）或体重，难以完整判断治疗是否覆盖代谢相关共病风险。近期，中华医学会内分泌学分会发布《多靶点肠促胰素受体激动剂在代谢相关共病管理中的应用专家共识》（以下简称共识），基于检索至2026年5月31日的证据形成30条推荐意见，覆盖人群识别、糖重管理、代谢相关共病、剂量递增、药物转换、安全性和随访[1]。本文沿“人群识别—糖重共管—共病证据—规范用药—长期随访”梳理共识的临床路径。一为什么需要“多靶点”：同一患者往往不只有一个管理目标多靶点肠促胰素受体激动剂在激活胰升糖素样肽-1（GLP-1）受体的基础上，同时作用于葡萄糖依赖性促胰岛素多肽（GIP）受体和（或）胰升糖素（GCG）受体。GIP/GLP-1双受体激动剂兼具葡萄糖依赖性促胰岛素分泌、食欲调节和改善脂肪组织功能等作用；GCG/GLP-1双受体激动剂则通过GCG通路进一步促进能量消耗、肝脏脂质氧化和内脏脂肪动员。GIP/GLP-1/GCG三受体激动剂及GLP-1/胰淀素复方制剂仍处于研究阶段[1]。对中国人群而言，BMI只是代谢风险评估的起点。相对较低BMI水平下即可出现腹型肥胖、内脏脂肪蓄积、胰岛素抵抗和MASLD，因此还需结合腰围、HbA1c、血脂、血压、肝肾功能、尿白蛋白/肌酐比值、肝脏影像及动脉粥样硬化性心血管疾病（ASCVD）、心衰和阻塞性睡眠呼吸暂停（OSA）风险识别代谢表型；老年人、绝经后女性和肌少症高风险者还应关注体成分、握力、步速与骨密度。药物选择需综合已获批适应证、共病证据、胃肠道耐受性、低血糖和肌肉骨骼风险、费用及患者偏好[1]。表1. 多靶点肠促胰素受体激动剂分类、作用机制与临床定位[1] 二把糖和体重一起管：疗效评价不再只看HbA1c 对2型糖尿病合并超重或肥胖者，共识建议在生活方式干预基础上，尤其针对腹型肥胖、MASLD、血脂异常或心血管-肾脏-代谢（CKM）风险较高的人群，依据适应证考虑已获批多靶点药物。疗效评价应同时纳入HbA1c达标、避免低血糖、体重与腰围下降，以及血压、血脂和心肾肝风险变化[1]。随机对照研究已同时覆盖血糖和体重结局。SURPASS-2研究中，替尔泊肽15 mg治疗40周后HbA1c和体重分别下降2.30个百分点和11.2 kg，司美格鲁肽1 mg组相应下降1.86个百分点和5.7 kg[2]。中国DREAMS-1研究中，玛仕度肽6 mg治疗24周的HbA1c降幅较安慰剂大2.02个百分点，81.8%的受试者达到HbA1c＜7.0%[3]。因此，疗效判断需同步观察血糖与体重；与胰岛素、磺脲类或格列奈类联用时，还应评估低血糖风险并调整剂量。表2. 多靶点肠促胰素受体激动剂治疗2型糖尿病的关键随机对照试验数据[1] 三体重降下来之后：3个月复评，达标后需进行维持治疗对于BMI≥28 kg/m²，或BMI≥24 kg/m²且至少合并1项体重相关代谢异常的成人，共识推荐在结构化生活方式干预基础上，依据获批适应证考虑多靶点肠促胰素类减重药物[1]。SURMOUNT-1研究中，无2型糖尿病的超重或肥胖成人接受替尔泊肽15 mg治疗72周，平均体重下降22.5%，62.9%的受试者体重下降至少20%[4]。GLORY-1研究中，中国无2型糖尿病的超重或肥胖成人接受玛仕度肽6 mg治疗48周，平均体重下降14.01%，49.5%的受试者体重下降至少15%；基线肝脏脂肪含量≥10%者的肝脂相对下降80.2%[5]。治疗3个月是判断早期应答和调整方案的关键节点。复评应同时观察体重下降比例、腰围、HbA1c、耐受性和依从性；若在剂量充分、依从性良好时体重下降不足5%，应重新评估饮食运动、继发性肥胖、合并用药及当前方案。达到阶段性治疗目标后，应及时评估并制定后续维持治疗方案[1]。表3 多靶点肠促胰素受体激动剂治疗肥胖的关键随机对照试验数据[1] 四从糖重指标到共病结局：肝脏、心肾与睡眠证据分层评价在代谢功能障碍相关脂肪性肝炎（MASH）领域，SYNERGY-NASH研究纳入伴中重度肝纤维化的MASH患者，替尔泊肽15 mg治疗52周后，MASH消退且无纤维化恶化的比例为62%，安慰剂组为10%；纤维化改善至少1期且无MASH恶化的比例分别为51%和30%[6]。GCG/GLP-1双受体激动剂已在临床研究中显示可降低肝脏脂肪含量。在合并动脉粥样硬化性心血管疾病的2型糖尿病患者中，SURPASS-CVOT研究以度拉糖肽为阳性对照。替尔泊肽在3点主要不良心血管事件（MACE-3）主要终点上达到非劣效性（HR=0.92，95.3%CI：0.83～1.01）；事后分析显示，其由6项事件构成的心肾复合终点风险亦低于度拉糖肽组（HR=0.84）[7]。SUMMIT研究则显示，在肥胖合并射血分数保留型心力衰竭患者中，替尔泊肽使心血管死亡或心衰恶化复合终点风险降低38%，同时改善健康状态和运动能力[8]。治疗方案应根据患者的具体共病和适应证统筹制定，并合理联合SGLT2抑制剂、肾素-血管紧张素系统阻断剂、他汀类药物及其他降压药物。对肥胖合并中重度OSA患者，SURMOUNT-OSA研究中替尔泊肽组呼吸暂停低通气指数较基线分别下降25.3和29.3次/h，43.0%和51.5%的受试者达到预设临床缓解标准[9]。共识建议在睡眠专科评估基础上将规范减重纳入综合治疗；持续气道正压通气的调整依据复查睡眠监测和专科判断。肥胖合并膝或髋骨关节炎者同样需规范减重，以减轻机械负荷并改善功能[1]。表4. 多靶点肠促胰素受体激动剂心血管与肾脏结局关键数据[1] 五剂量递增与药物转换：以耐受性和个体目标动态调整多靶点肠促胰素受体激动剂通常从低剂量起始，根据患者的胃肠道耐受情况逐步增量；如不良反应较明显，可适当延长剂量递增间隔。通常从说明书推荐的起始剂量开始，每4周或更长时间评估后再递增；老年、低体重、胃肠道敏感、慢性肾脏病、心衰或既往不耐受者，可将递增间隔延长至6～8周[1]。这一策略旨在减少恶心、呕吐、脱水、停药及容量不足相关肾功能波动。不同药物之间没有可靠的等效剂量换算。转换时可在原药下一个给药周期启动新药，并从新药起始剂量或较低剂量重新递增；因中重度胃肠道反应换药者，应待症状缓解后再启动。单靶点GLP-1受体激动剂在充分耐受剂量下治疗3～6个月，血糖或体重仍未达个体目标，或合并腹型肥胖、内脏脂肪显著蓄积及MASLD等共病时，可结合适应证评估升级至已获批多靶点药物；初诊即存在多重代谢共病特征者，也可在确认适应证、禁忌证和可及性后评估多靶点治疗[1]。六全程安全管理：兼顾胃肠道耐受、肌肉骨骼与长期随访恶心、腹泻、便秘、呕吐和消化不良多见于起始与递增阶段。少量多餐、减少高脂与油炸食物、保证水分摄入，并在症状明显时暂停递增、维持当前剂量或回退剂量，是主要处理路径。出现持续剧烈上腹痛、向背部放射痛、反复呕吐或发热时，应停药并评估胰腺炎和胆囊疾病；处方前还需询问甲状腺髓样癌及2型多发性内分泌腺瘤病个人或家族史[1]。减重期间，应同步监测肌量、肌力和骨骼风险。共识建议每周至少进行2次抗阻训练，并保证蛋白质摄入1.0～1.2 g·kg-1·d-1；老年、低体重、肌少症或骨质疏松高风险者在基线和随访中评估体成分、握力、步速和骨密度。已有中重度糖尿病视网膜病变或基线HbA1c较高者，启动前进行眼底评估并采用较缓慢的降糖与递增策略；妊娠和哺乳期禁用，有备孕计划者按说明书提前停药，通常至少提前2个月[1]。随访可按基线、4～8周、3个月、6个月和12个月推进：早期关注胃肠道反应、体重、血糖、心率和进食饮水；3个月判断疗效与依从性；6～12个月复评肝肾功能、尿白蛋白/肌酐比值、体成分、OSA症状及高风险项目。合并MASH高风险、慢性肾脏病、心衰、OSA、骨质疏松或肌少症者应进入多学科协作路径[1]。小结这份共识围绕多靶点药物的临床应用，提出从代谢表型评估、血糖与体重管理，到共病风险控制、剂量调整和长期随访的全程管理路径。对于中国患者，治疗决策需综合考虑BMI、腰围、内脏脂肪蓄积、MASLD及CKM风险；疗效评价除HbA1c和体重变化外，还应关注相关共病的改善情况、治疗耐受性、肌肉和骨骼健康以及治疗依从性。临床应根据适应证及相应人群的循证证据选择药物，并通过定期随访评估疗效和安全性，及时调整治疗方案，实现代谢相关共病的长期规范管理。参考文献上下滑动可查看 [1] 中华医学会内分泌学分会. 多靶点肠促胰素受体激动剂在代谢相关共病管理中的应用专家共识[J]. 中华内分泌代谢杂志, 2026, 42(8): 733-744. DOI: 10.3760/cma.j.cn311282-20260602-00259.[2] Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes[J]. N Engl J Med, 2021, 385(6): 503-515. DOI: 10.1056/NEJMoa2107519.[3] Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes[J]. Nature, 2026, 652(8108): 174-180. DOI: 10.1038/s41586-025-10026-w.[4] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022, 387(3): 205-216. DOI: 10.1056/NEJMoa2206038.[5] Ji L, Jiang H, Bi Y, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight[J]. N Engl J Med, 2025, 392(22): 2215-2225. DOI: 10.1056/NEJMoa2411528.[6] Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis[J]. N Engl J Med, 2024, 391(4): 299-310. DOI: 10.1056/NEJMoa2401943.[7] Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes[J]. N Engl J Med, 2025, 393(24): 2409-2420. DOI: 10.1056/NEJMoa2505928.[8] Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity[J]. N Engl J Med, 2025, 392(5): 427-437. DOI: 10.1056/NEJMoa2410027.[9] Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity[J]. N Engl J Med, 2024, 391(13): 1193-1205. DOI: 10.1056/NEJMoa2404881. 读者福利：点击文末【阅读原文】，查看文献原文。声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《心肾代谢时讯》编辑部）

临床研究

2026-09-07

·微信

超1.3万人3期研究支持！礼来Mounjaro再获FDA批准

礼来（Eli Lilly and Company）宣布，美国FDA已批准Mounjaro（tirzepatide，替尔泊肽）用于降低具有心血管事件高风险的2型糖尿病成人患者发生主要不良心血管事件（MACE）的风险，包括心血管死亡、非致死性心肌梗死或非致死性卒中。此次批准主要基于SURPASS-CVOT试验结果。这是一项事件驱动、随机、双盲、平行分组3期临床试验，旨在评估Mounjaro与GLP-1受体激动剂Trulicity（dulaglutide）在患有2型糖尿病且已确诊动脉粥样硬化性心血管疾病（ASCVD）的成人患者中的疗效和安全性。该试验持续约5年，中位随访时间为4年。研究共纳入13299名受试者，并按照1：1随机分组，分别接受Mounjaro（15 mg或最大耐受剂量）或Trulicity（1.5 mg）每周一次皮下注射。分析显示，与活性对照药Trulicity相比，Mounjaro在降低主要不良心血管事件（MACE-3）风险方面达到非劣效性标准。MACE-3是一项由心血管死亡、心肌梗死或卒中组成的复合终点。在中位随访210.1周期间，Mounjaro组的MACE-3发生率较Trulicity组低8%，首次发生MACE的估计风险比为0.92（95.3% CI：0.83，1.01）。Mounjaro达到预设的非劣效性标准，但未确立相较Trulicity的优效性。该研究的完整结果已发表于《新英格兰医学杂志》（NEJM）。 Mounjaro的安全性和耐受性总体与其已知安全性特征一致。在SURPASS-CVOT试验中，Mounjaro最常报告的不良事件为与胃肠道相关事件，严重程度通常为轻度至中度，且主要发生于剂量递增阶段。 Mounjaro是一款GIP和GLP-1双受体激动剂。此前，Mounjaro已获批作为饮食和运动的辅助治疗，用于改善成人及10岁及以上2型糖尿病儿童患者的血糖水平。Trulicity是一款每周注射一次的GLP-1受体激动剂，获批作为饮食和运动的辅助治疗，用于改善成人及10岁及以上2型糖尿病儿童患者的血糖水平。Trulicity还获批用于降低2型糖尿病成人患者发生主要心血管事件的风险，包括心血管死亡、心肌梗死或卒中，适用人群包括已确诊心血管疾病或具有多种心血管危险因素的患者。参考资料： [1] FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Retrieved August 28, 2026 from https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

临床3期临床结果

2026-09-07

·医药魔方ByDrug

超1.3万人3期研究支持！礼来Mounjaro再获FDA批准

临床3期临床结果临床成功加速审批

100 项与度拉糖肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09889	度拉糖肽	A10BJ05	DB09045

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	美国	Eli Lilly & Co.	2014-09-18

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
低血糖	临床3期	日本	Eli Lilly & Co.	2021-04-13
心血管疾病	临床3期	美国	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	阿根廷	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	澳大利亚	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	巴西	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	保加利亚	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	加拿大	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	智利	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	哥伦比亚	Eli Lilly & Co.	2011-07-22
心血管疾病	临床3期	捷克	Eli Lilly & Co.	2011-07-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04255433 (SURPASS-CVOT \| SURPASS, CTgov)	临床3期	2型糖尿病	13,299	Dulaglutide	觸鏇醖築網憲窪齋鹽壓 = 襯衊鬱觸膚選獵憲壓製廠蓋淵蓋構遞鏇繭壓鏇 (廠憲獵醖遞鹹鬱範構築, 鏇淵醖鹽簾遞簾餘鬱齋 ~ 鑰廠顧廠鏇齋範衊衊選) 更多	-	2026-07-08
ADA2026	N/A	2型糖尿病 \| 轻度认知障碍	1,320	GLP-1 RAs	選襯膚膚願製鬱鹹簾遞(鹹願艱鹹鑰艱憲蓋築獵): ARD = -4.9 (95.0% CI, -9.4 ~ -0.4) 更多	积极	2026-06-20
				DPP4i
NCT04255433 (Pubmed \| JAMA Cardiol)	临床3期	心血管疾病 \| 2型糖尿病	13,165	Tirzepatide	壓選餘鹹鹹廠淵鏇鹹憲(觸鹽鬱構廠製網糧餘餘) = 獵製鬱製願範製糧醖鹽蓋築窪窪窪廠積製鹹壓 (鏇積顧窪遞積觸積衊繭 ) 更多	积极	2026-06-01
				Dulaglutide	壓選餘鹹鹹廠淵鏇鹹憲(觸鹽鬱構廠製網糧餘餘) = 網鏇壓遞淵繭廠鹽衊鹽蓋築窪窪窪廠積製鹹壓 (鏇積顧窪遞積觸積衊繭 ) 更多
ASCO2026	N/A	HER2阳性转移性乳腺癌 HR+/HER2-	1,208	GLP-1 RA+ET+CDK4/6i	-	积极	2026-05-29
				ET+CDK4/6i alone	鏇憲齋襯築選膚鑰衊壓(餘願淵選餘顧鏇壓襯窪) = 築願鏇觸顧齋鑰遞餘夢蓋艱淵選鹽觸憲壓簾鑰 (築衊齋衊網願鹽製廠蓋 )
DDW2026	N/A	肝硬化	119,317	GLP-1 RAs (semaglutide, liraglutide, dulaglutide, tirzepatide)	淵壓淵窪簾淵衊鹹淵醖(繭壓淵觸鏇積糧顧憲簾): OR = 0.38 (95.0% CI, 0.36 ~ 0.41) 更多	积极	2026-05-02
				Non-GLP-1 RA users
DDW2026	N/A	代谢功能障碍相关的脂肪肝病	400	GLP-1 RAs	鏇選窪齋獵遞觸餘醖顧(選遞蓋鬱窪獵鑰餘膚醖): OR = 0.22 (95.0% CI, 0.12 ~ 0.39) 更多	积极	2026-05-02
				Non-GLP-1 RAs
AAD2026	N/A	注射部位反应	15,780	Semaglutide	顧鏇築鹹醖範觸襯選願(鏇醖衊鬱鏇簾蓋範築顧) = common AEs were rash (26.1%), pruritus (22.1%), alopecia (14.8%), hyperhidrosis (14.6%), and urticaria (3.5%). 壓鹹壓顧構壓窪鏇蓋顧 (襯選蓋夢顧憲積獵顧衊 )	积极	2026-03-27
				Liraglutide
NCT03204396 (Pubmed \| Eur J Prev Cardiol)	临床2期	尼古丁成瘾	255	Dulaglutide 1.5mg	窪構鑰壓鑰壓壓壓窪鹹(廠齋簾夢鹽網壓衊鬱憲) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation 憲膚願衊築獵衊齋鬱獵 (選獵顧壓鬱鑰壓鑰製鹽 )	-	2025-10-10
NCT05680129 (EECOH-2, Literature) 人工标引	临床3期	2型糖尿病	621	ecnoglutide 0.6 mg	鬱憲築膚壓衊衊醖鏇鏇(顧糧鏇齋繭齋襯鹹夢窪) = 淵淵襯膚顧網衊餘廠憲簾選網膚鬱願醖獵鬱淵 (齋網簾憲餘艱遞窪範壓 ) 更多	积极	2025-08-22
				ecnoglutide 1.2 mg	鬱憲築膚壓衊衊醖鏇鏇(顧糧鏇齋繭齋襯鹹夢窪) = 簾窪範構構願簾憲鬱衊簾選網膚鬱願醖獵鬱淵 (齋網簾憲餘艱遞窪範壓 ) 更多
NCT04255433 (SURPASS-CVOT, PRNewswire) 人工标引	临床3期	2型糖尿病 \| 动脉粥样硬化	13,299	Mounjaro (tirzepatide)	鏇簾製窪構蓋鏇獵壓衊(鏇窪築獵築齋選鏇構鏇): HR = 0.92 (95.3% CI, 0.83 ~ 1.01) 达到更多	非劣	2025-07-31
				Trulicity (dulaglutide)